Kidney cancer develops when cells in the kidney grow abnormally and form a malignant tumour. The kidneys are two bean-shaped organs that filter the blood, remove waste, regulate fluid and electrolyte balance, and produce hormones involved in blood pressure and red-blood-cell production.
Renal cell carcinoma (RCC) is the most common kidney cancer in adults. The principal subtypes are clear cell, papillary, and chromophobe RCC. Less common subtypes include collecting-duct carcinoma, renal medullary carcinoma, translocation-associated RCC, and other molecularly defined tumours. Cancers arising in the renal pelvis are generally urothelial carcinomas and are assessed and treated differently.
At Apollo Cancer Centres, kidney cancer care is planned by a multidisciplinary team that may include uro-oncologists, medical oncologists, radiation oncologists, interventional radiologists, radiologists, nuclear-medicine specialists, pathologists, nephrologists, genetic counsellors, and supportive-care specialists. Treatment is personalised according to the tumour's size, location, stage, subtype, molecular features, kidney function, and the patient's overall health.
Risk Factors for Kidney Cancer
Kidney Cancer Signs and Symptoms
How Kidney Cancer Is Diagnosed
Diagnosis begins with a review of symptoms, medical history, smoking history, kidney function, medications, occupational exposure, and family history. The doctor may examine the abdomen and assess blood pressure, swelling, or other signs of kidney or systemic disease.
Imaging is central to diagnosis and staging. Some kidney tumours can be characterised sufficiently on imaging to proceed directly to surgery. A biopsy is used when its result is expected to influence management.
Ultrasound
Ultrasound may be the first test used to evaluate blood in the urine or an abnormality detected during another examination. It can help distinguish a fluid-filled cyst from a solid renal mass. Some complex cysts and small solid tumours require further assessment with contrast-enhanced CT or MRI.
CT Scan
A multiphase contrast-enhanced CT scan is commonly used to assess a suspected kidney tumour. It provides information about:
Tumour size and position
Enhancement pattern and internal features
Involvement of nearby fat, organs, or lymph nodes
Extension into the renal vein or inferior vena cava
The opposite kidney
Possible spread to the lungs, liver, bones, or other sites
A renal-protocol CT obtains images at different stages after contrast administration. Kidney function and previous contrast reactions are considered before the test.
MRI
MRI may be used when CT contrast is unsuitable, when CT findings are unclear, or when more detailed assessment of blood-vessel involvement is needed. It is particularly useful when the tumour may extend into the renal vein or inferior vena cava. MRI may also help characterise complex cystic masses and selected small renal tumours.
Chest Imaging
A chest CT is commonly performed when staging a confirmed or strongly suspected RCC because the lungs are a frequent site of distant spread. A chest X-ray may be sufficient in selected patients with a very low risk of metastasis.
Bone Scan
A bone scan is not routinely required for every kidney tumour. It may be performed when the patient has bone pain, abnormal blood-test results, or other findings suggesting skeletal involvement.
PET-CT
Standard FDG PET-CT is not routinely used to diagnose or stage all renal cell carcinomas because kidney excretion of the tracer can limit assessment of the primary tumour. It may be helpful in selected recurrent or metastatic cases when other imaging is inconclusive.
Percutaneous Core Needle Biopsy
A renal-mass biopsy is usually performed under ultrasound or CT guidance. A hollow needle is passed through the skin to collect tissue from the tumour, generally under local anaesthesia with sedation when required.
Biopsy may be recommended:
Before thermal ablation
Before systemic treatment when there is no previous tissue diagnosis
When imaging cannot reliably distinguish cancer from a benign tumour
When lymphoma, metastasis, infection, or another condition is possible
Before active surveillance in selected patients when the result could change management
Fine-Needle Aspiration
Fine-needle aspiration collects individual cells through a thin needle. It may be used in selected circumstances but usually provides less information about tumour architecture than a core biopsy.
Surgical Specimen
When imaging strongly suggests RCC and surgery is appropriate, a preoperative biopsy may not be necessary. The diagnosis and subtype are then established by examining the removed tumour or kidney. A non-diagnostic biopsy does not prove that a mass is benign. Repeat biopsy or surgical management may be considered according to the imaging findings and clinical risk.
Laboratory
Blood, urine, and tumour-tissue assessment help evaluate kidney function, confirm the diagnosis, determine prognosis, and guide treatment.
Evaluation may include:
Urinalysis: Detects visible or microscopic blood, protein, infection, or other urinary abnormalities.
Complete blood count: May identify anaemia or, less commonly, an increased red-blood-cell count caused by tumour-related hormone production.
Kidney-function tests: Creatinine and estimated glomerular filtration rate help assess baseline kidney function and plan imaging, surgery, and systemic treatment.
Liver-function tests: May identify liver involvement or abnormalities associated with advanced RCC.
Blood chemistry: Calcium, electrolytes, albumin, and lactate dehydrogenase may provide information relevant to general health and prognosis.
Histopathology: Confirms whether the mass is malignant and identifies the RCC subtype or another tumour type.
Tumour grading: The WHO/ISUP grade evaluates nuclear features and helps estimate how aggressively selected RCC subtypes may behave.
Pathological assessment: Records tumour size, local extension, blood-vessel involvement, lymph-node findings, surgical margins, necrosis, and sarcomatoid or rhabdoid features where present.
Immunohistochemistry: Helps distinguish RCC subtypes and separate primary kidney cancer from tumours that have spread from another organ.
Molecular testing: May help classify an unusual tumour or identify potentially relevant alterations in selected advanced cancers.
Germline genetic testing: May be recommended for patients diagnosed at a young age, those with bilateral or multifocal tumours, unusual histology, associated clinical features, or a relevant family history.
There is no blood or urine tumour marker that can reliably diagnose or screen for RCC. Laboratory findings must be interpreted alongside imaging and pathological assessment.
Kidney cancer is staged using the TNM system, which considers the primary tumour, regional lymph nodes, and distant spread.
Kidney cancer may be broadly described as:
Stage I: The tumour is 7 cm or smaller and remains confined to the kidney.
Stage II: The tumour is larger than 7 cm but remains confined to the kidney.
Stage III: The tumour has extended into a major vein or tissue around the kidney, or cancer is present in regional lymph nodes, without distant spread.
Stage IV: The tumour has grown beyond the tissue surrounding the kidney or has spread to distant lymph nodes or organs.
The stage, tumour subtype, grade, sarcomatoid or rhabdoid features, areas of necrosis, and the patient's overall health help determine prognosis and treatment.
For metastatic RCC, clinical risk models may also use factors such as general health, blood counts, calcium levels, and the interval between diagnosis and treatment to classify the disease into prognostic groups.
How Kidney Cancer Is Treated
Partial Nephrectomy
Partial nephrectomy removes the tumour with a margin of surrounding tissue while preserving the rest of the kidney. It is generally preferred for small, localised tumours when technically feasible.
It may also be particularly important for patients with:
A tumour in a solitary functioning kidney
Tumours affecting both kidneys
Pre-existing chronic kidney disease
An inherited condition that may cause additional kidney tumours
Partial nephrectomy may be performed using robotic, laparoscopic, or open surgery. The approach depends on tumour size, position, complexity, kidney function, and surgical expertise.
Radical Nephrectomy
Radical nephrectomy removes the entire affected kidney and surrounding fatty tissue. The adrenal gland or nearby lymph nodes may also be removed when clinically indicated. It may be recommended for a large or centrally located tumour when partial nephrectomy cannot achieve adequate cancer removal while preserving useful kidney function. Most people can live with one healthy kidney. Kidney function should nevertheless be monitored after surgery.
Lymph-Node Dissection
Enlarged or suspicious regional lymph nodes may be removed during surgery. Routine removal of normal-appearing lymph nodes has not shown the same benefit for every patient and is considered according to the individual clinical situation.
Venous Tumour-Thrombus Surgery
RCC can extend into the renal vein or inferior vena cava. Surgery may involve removal of the kidney and tumour from the affected vein. These operations can be complex and may require urological, vascular, liver, or cardiothoracic surgical expertise, depending on how far the tumour extends.
Metastasectomy
Removal of one or a limited number of metastases may be considered for selected patients when complete treatment of visible disease appears possible. The decision depends on the location and number of metastases, timing of recurrence, tumour biology, symptoms, general health, and available systemic treatments.
Cytoreductive Nephrectomy
Removing the primary kidney tumour in the presence of metastatic disease is not appropriate for every patient. It may be considered selectively according to symptoms, metastatic burden, clinical risk, response to systemic treatment, and whether most visible disease can be controlled.
Immunotherapy
Immune-checkpoint inhibitors help the immune system recognise and attack cancer cells. They are central to the treatment of many advanced RCCs.
Depending on the clinical situation, immunotherapy may be given:
In combination with another immunotherapy medicine
In combination with a targeted therapy
As postoperative treatment for selected patients with clear-cell RCC at a high risk of recurrence
Treatment selection depends on tumour subtype, risk group, previous therapy, organ function, autoimmune conditions, and potential side effects. Immune-related effects may involve the skin, bowel, liver, lungs, thyroid, adrenal glands, or other organs and require prompt medical assessment.
Targeted Therapy
Targeted medicines commonly block pathways involved in blood-vessel formation or cancer-cell growth. These include vascular endothelial growth factor receptor tyrosine-kinase inhibitors and, in selected settings, mTOR inhibitors or medicines targeting other molecular pathways. They may be used alone or with immunotherapy in advanced disease. Possible effects include high blood pressure, diarrhoea, fatigue, mouth soreness, skin changes, liver abnormalities, thyroid dysfunction, and altered kidney function.
Chemotherapy
Conventional chemotherapy has limited effectiveness against most common RCC subtypes and is not routinely used for clear-cell RCC. It may be considered for selected uncommon tumours, such as collecting-duct carcinoma, renal medullary carcinoma, or other cancers with particular histological features.
Adjuvant Therapy
After surgery, selected patients with clear-cell RCC at a high risk of recurrence may be offered adjuvant immunotherapy. The potential benefits and immune-related risks should be discussed carefully. Adjuvant treatment is not required for every patient, and eligibility depends on the pathological findings and current clinical guidance.
Treatment for Non-Clear-Cell RCC
Papillary, chromophobe, collecting-duct, translocation-associated, and other uncommon RCCs may behave differently from clear-cell cancer. Treatment may involve surgery, targeted therapy, immunotherapy, chemotherapy, or a clinical trial, depending on the subtype and stage. Specialist pathological review is particularly important.
External Beam Radiation Therapy
RCC is not usually treated with conventional radiation alone when complete surgical removal is feasible. Radiation may nevertheless be used:
To relieve pain from bone metastases
To treat bleeding or pressure caused by the primary tumour
To manage brain or spinal metastases
To reduce the risk of fracture or spinal cord compression
To control selected recurrent or metastatic deposits
Stereotactic Body Radiation Therapy
Stereotactic body radiation therapy delivers a highly focused dose over a limited number of sessions.
It may be considered for:
Selected localised tumours when surgery or ablation is unsuitable
A limited number of metastatic sites
A growing metastatic lesion while other disease remains controlled
Selected recurrent tumours
Suitability depends on tumour size, location, proximity to the bowel or other sensitive structures, kidney function, previous treatment, and overall disease burden.
Stereotactic Radiosurgery
Stereotactic radiosurgery may be used for selected brain metastases. Treatment is planned according to the number, size, location, symptoms, and overall extent of disease.
Cryoablation
Cryoablation inserts one or more probes into the tumour and uses very low temperatures to destroy cancer cells. It is commonly performed through the skin under CT or ultrasound guidance. It may be considered for selected small tumours, particularly when surgery would carry substantial risk or preservation of kidney tissue is important.
Radiofrequency Ablation
Radiofrequency ablation uses heat generated by electrical energy to destroy tumour tissue. It may be used for selected small, accessible kidney tumours.
Microwave Ablation
Microwave ablation uses electromagnetic energy to heat and destroy tumour tissue. Its suitability depends on tumour size, position, local expertise, and proximity to surrounding structures. A renal-mass biopsy is generally performed before or during ablation. Follow-up imaging is required because ablation does not provide a complete surgical specimen and local persistence or recurrence can occur.
The outlook for kidney cancer depends mainly on its stage, subtype, grade, and whether the tumour can be completely removed. Small cancers confined to the kidney often have a favourable prognosis after treatment.
Follow-up after treatment may include clinical assessment, blood pressure and kidney-function monitoring, and imaging of the abdomen and chest. The schedule depends on the pathological stage, risk of recurrence, treatment received, and remaining kidney function.
Why Choose ACC for Kidney Cancer Treatment